Display options
Cite
Powers JF, Tsokas P, Tischler AS. The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro. Endocr Pathol. 1998;9(1):325-331doi: 10.1007/BF02739692.
Powers, J. F., Tsokas, P., & Tischler, A. S. (1998). The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro. Endocrine pathology, 9(1), 325-331. https://doi.org/10.1007/BF02739692
Powers, James F., et al. "The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro." Endocrine pathology vol. 9,1 (1998): 325-331. doi: https://doi.org/10.1007/BF02739692
Powers JF, Tsokas P, Tischler AS. The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro. Endocr Pathol. 1998;9(1):325-331. doi: 10.1007/BF02739692. PMID: 12114780.
Copy Download .nbib Format: NLM
Share it on

Endocr Pathol. 1998;9(1):325-331. doi: 10.1007/BF02739692.

The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro.

Endocrine pathology

James F. Powers, Panayiotis Tsokas, Arthur S. Tischler

PMID: 12114780 DOI: 10.1007/BF02739692

Abstract

Activating mutations of the receptor tyrosine kinase, ret, are associated with multiple endocrine neoplasia type 2A (MEN 2A). However, the mechanisms leading to tumor development are unclear. Glial-derived neurotrophic factor (GDNF) activates wild-type ret via interaction with a second receptor, GFR a-l. We have utilized GDNF to stimulate normal and neoplastic chromaffin cells in order to ask whether ret activation is mitogenic. Cells from three normal adult adrenal medullas, one sporadic pheochromocytoma, and three MEN-2A pheochromocytomas were labeled with bromodeoxyuridine (BrdU) for 12 d in the presence or absence of GDNF or nerve growth factor (NGF), which is known to stimulate neurite outgrowth, but not proliferation in human chromaffin and pheochromocytoma cell cultures. Responses to GDNF and NGF were comparable, except for two MEN-2A pheochromocytomas that responded minimally to GDNF and robustly to NGF. These tumors responded to GDNF biochemically, as measured by phosphorylation of mitogen-activated protein kineses, despite their weak morphological responses. Our findings suggest that activation of ret may not be sufficient to produce chromaffin cell hyperplasia or neoplasia directly by stimulating cell proliferation. However the possibility that altered cell-cell or cell-substrate interactions might cause responses to become differ entiative rather than proliferative in vitro has not been ruled out. We also demonstrate, for the first time, that at least some human pheochromocytomas with an MEN-2A ret mutation respond to a normal ret ligand. This responsiveness could be mediated by a remaining normal ret allele or by other mechanisms.

References

  1. Cell. 1995 Jan 27;80(2):179-85 - PubMed
  2. J Neurosci. 1997 Aug 15;17(16):6189-202 - PubMed
  3. Nature. 1997 Jun 12;387(6634):717-21 - PubMed
  4. Nature. 1996 Jul 4;382(6586):80-3 - PubMed
  5. Nature. 1996 Jun 27;381(6585):785-9 - PubMed
  6. Biochem Biophys Res Commun. 1996 Jan 17;218(2):606-9 - PubMed
  7. Neurosci Lett. 1997 Jul 18;230(2):73-6 - PubMed
  8. J Neurosci. 1998 Jun 1;18(11):4008-21 - PubMed
  9. Lab Invest. 1980 Nov;43(5):399-409 - PubMed
  10. Neuron. 1997 Sep;19(3):485 - PubMed
  11. Science. 1982 Oct 29;218(4571):474-5 - PubMed
  12. Cell. 1992 Jan 24;68(2):271-81 - PubMed
  13. N Engl J Med. 1988 Feb 25;318(8):478-84 - PubMed
  14. J Neurosci. 1984 May;4(5):1398-404 - PubMed
  15. Nature. 1996 Dec 5;384(6608):467-70 - PubMed
  16. J Histochem Cytochem. 1992 Jul;40(7):1043-5 - PubMed
  17. Mol Cell. 1997 Dec;1(1):13-23 - PubMed
  18. J Neurosci. 1998 Apr 15;18(8):3059-72 - PubMed
  19. J Immunol. 1997 Sep 1;159(5):2274-81 - PubMed

Publication Types